zadnja posodobitev :
19/11/2024
Različen   Octreotide acetate  
Brizgalka
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost način aplikacije Viri pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Akroken Mehika
Badastin Ekvador
Bendatreotid Egipt
Cryostatin Mehika
Gasterina Argentina, Čile
Jintrotide Peru
Longastatina Italija
Nomactril Mehika
Ocphyl Kanada
Octate Indija
Octide Indija
Octotide Ekvador
Octreotid Nemčija
Octreotida Španija
Octreotide Kanada, Velika Britanija, Združene države Amerike
Octride Ekvador, Kolumbija
Samilstin Italija
Sandostatin Argentina, Avstralija, Avstrija, Brazilija, Čile, Danska, Ekvador, Finska, Grčija, Irska, Islandija, Kanada, Luksemburg, Madžarska, Malezija, Nemčija, Norveška, nova Zelandija, Poljska, Romunija, Slovenija, Španija, Švedska, Švica, Turčija, Velika Britanija, Združene države Amerike, Združeni arabski emirati
Sandostatina Italija, Portugalska
Sandostatine Belgija, Francija, Maroko, Nizozemska, Portugalska
Secrestat Kolumbija
Siroctid Belgija
Viri   Brizgalka   Viri : Octreotide acetate  
Tip objava
127 časopis Ripley RG, Ritchie DJ, Holstad SG.
Stability of octreotide acetate in polypropylene syringes at 5 and -20°C.
Am J Health-Syst Pharm 1995 ; 52: 1910-1911.
294 časopis Stiles ML, Allen LV, Resztak KE, Prince SJ.
Stability of octreotide acetate in polypropylene syringes.
Am J Hosp Pharm 1993 ; 50: 2356-2358.
301 časopis Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
466 časopis Ritchie DJ, Holstad SG, Westrich TJ, Hirsch JD, O'Dorisio TM.
Activity of octreotide acetate in a total nutrient admixture.
Am J Hosp Pharm 1991 ; 48: 2172-2175.
1415 časopis Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1508 časopis Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1902 časopis Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
2087 časopis Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 časopis Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 časopis Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2404 časopis Fielding H, Kyaterekera , Skellern GG, Tettey JN, McDade JR, ZMsuya Z, Watson DG, Urie J.
The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes
Palliative Med 2000 ; 14: 205-208.
3216 časopis Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3408 časopis Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3767 časopis Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3824 časopis Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3828 poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3948 časopis Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 časopis Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4086 Traduction Laboratorij Octréotide - (Sandostatine®)- Résumé des caractéristiques du produit
Novartis Pharma 2017
4145 časopis Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434 časopis Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4528 časopis Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 časopis Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 časopis Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4768 časopis Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H.
Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019.
Journal of Nippon Medical school 2023
4801 časopis Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales